Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anthem BiosciencesNSE:ANTHEM -0.93%34 Gross Margin % is 64.73% as of Mar. 2026, which is 5% above its 10-year median of 61.76. GuruFocus rates NSE:ANTHEM with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Anthem Biosciences ranks better than 52.73% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Anthem Biosciences had a gross margin of 64.73% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Anthem Biosciences Gross Margin % Related Terms
Anthem Biosciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Anthem Biosciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ANTHEM vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Anthem Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anthem Biosciences Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anthem Biosciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Anthem Biosciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Anthem Biosciences (NSE:ANTHEM) has a Gross Margin % of 64.73% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Anthem Biosciences and its competitors. This is near median its historical median of 61.76. Over the past decade, Anthem Biosciences' Gross Margin % has ranged from 57.76 to 67.90. According to the industry distribution chart, Anthem Biosciences ranks #346 out of 732 companies in the Biotechnology industry, placing it in the top 47.3%.
Is Anthem Biosciences' Gross Margin % too high?
Anthem Biosciences' current Gross Margin % of 64.73% is near median its 10-year median of 61.76. Over the past 10 years, this metric has ranged from a low of 57.76 to a high of 67.90. The Biotechnology industry median Gross Margin % is 60.91. Anthem Biosciences' value of 64.73% is 6.3% above this industry median. Based on the distribution chart, Anthem Biosciences ranks #346 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Anthem Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anthem Biosciences ranks #346 out of 732 companies for Gross Margin %. This puts Anthem Biosciences in the upper half of its industry. The industry median Gross Margin % is 60.91. Anthem Biosciences' value of 64.73% is 6.3% above this benchmark. Historically, Anthem Biosciences' own Gross Margin % has ranged from 57.76 to 67.90 over the past decade. While the company's 10-year median is 61.76 vs. the industry median of 60.91, Anthem Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anthem Biosciences's current Gross Margin % of 64.73% is 6.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Anthem Biosciences and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anthem Biosciences's current Gross Margin % is 64.73%, which is near median its own 10-year median of 61.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Gross Margin % of 64.73%. The current Gross Margin % is 64.73%, which is near median its 10-year median of 61.76 and 6.3% above the Biotechnology industry median of 60.91. Anthem Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Gross Margin % is 64.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
34GF Score
Get the complete analysis for NSE:ANTHEM
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ANTHEM has been successfully added to your 
